Group A | Group B | |
---|---|---|
(XELIRI-Bev) | (FOLFIRI-Bev) | |
N = 143 | N = 142 | |
Age | ||
Median (range) | 66 (28–84) | 66 (32–80) |
N (%) | N (%) | |
<60 | 40 (28) | 44 (31) |
≥60 | 103 (72) | 98 (69) |
Gender | ||
Male | 79 (55) | 92 (65) |
Female | 64 (45) | 50 (35) |
PS (ECOG) | ||
0 | 92 (64) | 94 (66) |
1 | 37 (26) | 40 (28) |
2 | 12 (8) | 6 (4) |
Missing data | 2 (2) | 2 (2) |
Primary location | ||
Colon | 98 (68) | 85 (60) |
Rectum | 35 (25) | 44 (31) |
Rectosigmoid | 3 (2) | 8 (6) |
Rectosigmoid and cecum | 1 (1) | – |
Misssing data | 6 (4) | 5 (3) |
Stage at diagnosis | ||
I | 2 (1) | 3 (2) |
II | 5 (4) | 11 (8) |
III | 23 (16) | 26 (18) |
IV | 107 (75) | 90 (63) |
Missing data | 6 (4) | 12 (9) |
Previous adjuvant chemotherapy | ||
No | 114 (80) | 112 (79) |
Yes | 27 (19) | 27 (19) |
Missing data | 2 (1) | 3 (2) |
Previous surgery | 114 (80) | 123 (87) |
Symptomatic disease | ||
Yes | 70 (49) | 66 (46) |
No | 56 (39) | 54 (38) |
Missing data | 17 (12) | 22 (16) |
Organs involved | ||
Liver | 103 (72) | 101 (71) |
Lung | 51 (36) | 39 (28) |
Other | 54 (38) | 61 (43) |
Number of organs involved | ||
1 | 84 (59) | 85 (60) |
2 | 39 (27) | 43 (30) |
≥3 | 19 (13) | 14 (10) |
Missing data | 1 (1) | – |